Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Brexit

UK Agency Boss Hudson Leaves Brexit Challenge To Successor

A new leader is needed for MHRA as UK agency CEO Ian Hudson announces he'll leave next September. Someone else will have to reshape and guide the agency after Brexit.
Europe Brexit Regulation

Health Must Be At Center Of Post-Brexit Relationship, Say Industry & NHS Bodies

UK industry and National Health Service bodies say that the “political declaration” on the future UK-EU relationship fails to address key public health issues such as regulatory cooperation, collaboration in science and innovation, and tackling counterfeit medicines.
Brexit Regulation Europe

Latest From Brexit

Brexit Delays Key ATMP Guideline Update – EMA Says Perhaps Not So Bad

The European Medicines Agency's proposal to revise its decade-old guideline on safety and efficacy follow-up and risk management of advanced therapies has generated keen interest among stakeholders. The update of this key guideline, however, is on hold due to Brexit. 
Europe Brexit

EMA Set For More Staff Losses & Activity Cuts Next Year

The latest EMA management board meeting heard an update on the situation regarding Brexit-related staff losses and recruitment, and was told that an additional set of temporary suspensions or reductions in its activities might be necessary from the beginning of 2019.
Brexit Regulation

Lessons From A Life Sciences Lifetime: An Interview With Sir John Bell

Professor Sir John Bell talks to In Vivo about how the life sciences sector has evolved during his career, lessons he has learned along the way, and the biggest challenges and changes ahead for the industry in 2019.

Leadership Brexit

UK Government Prioritizes Medical-Device Transport In No-Deal Brexit

The UK government has been working on plans to ensure medical devices, among other goods, can still "flow into the country, and won't be delayed by additional controls and checks."

Brexit Policy

Ensuring UK Medicines Supply Under No-Deal Brexit “Just Got Harder”

Pharmaceutical industry bodies are exasperated by the lack of detail in the UK government’s update on contingency planning for the supply of medicines in the event of a no-deal Brexit.
Brexit United Kingdom

UK Receives £1bn Confidence Boost From Industry Investment In Life Sciences Sector

The international biopharma industry is backing the UK life sciences sector, with UCB spearheading the charge with a £1bn commitment to R&D in the nation still in a state of flux regarding its exit from the European Union in 2019.

United Kingdom Deals

EU Regulatory Roundup, November 2018: 'Implant Files' Dominate, While Brexit/New Reg Issues Rumble On

The medtech sector was already quite overwhelmed with the new EU regulations and Brexit uncertainties. Now add into the mix the impact of the global journalistic Implant Files investigation.

Europe United Kingdom

MHRA Tackles Post Brexit Distribution Worries

Companies importing medicines from the EU into the UK in the event of a no-deal Brexit could face a lot of complications. The UK medicines regulator, the MHRA, has come up with one idea for easing the import requirements in such a scenario.
Brexit United Kingdom

UK Smooths Clinical Trial Pathway To Reassure Companies With Brexit Jitters

The UK is revising its clinical trial processes to align them with the new EU Clinical Trials Regulation so that companies can seek authorization just as easily in the UK as in other EU member states, irrespective of the situation after Brexit.
Brexit Clinical Trials
See All